Navigation Links
Abaxis Announces Appointment of New Distribution Partner in Japan
Date:10/30/2007

UNION CITY, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX) a medical and veterinary manufacturer of point-of-care blood analysis systems, announced today that Central Scientific Commerce, Inc., (CSC) has signed an exclusive distribution agreement to distribute the complete line of Abaxis medical and veterinary products in Japan. With offices in Tokyo, Osaka, Fukuoka and Sapporo, CSC is one of the leading medical and veterinary products distributors in the Japanese market. CSC is a subsidiary of GSI Creos Corporation, established in 1931 and headquartered in Tokyo, Japan with a total of twenty-seven subsidiaries and nine associated companies.

Mr. Clint Severson, chairman and chief executive officer of Abaxis, Inc. commented, "We are pleased to be working with Central Scientific Commerce to embed our leading-edge point-of-care products in the Japanese healthcare market. We have great respect for their professionalism and the solid reputation that they have built over the years in their markets. We firmly believe that this collaboration will result in expanded market share in the years to come and the recognition of Abaxis as a trusted partner in the healthcare system of Japan."

Mr. Aritaka Kasnayama, managing director of Central Scientific Commerce, Inc., said, "We are delighted to be working with Abaxis to develop the market in Japan. We believe that Abaxis technology can result in more timely patient diagnosis and treatment regimes leading to improved patient outcomes and quality of life. We think that the appropriate healthcare providers in Japan will adopt this technology and work hard to bring these benefits to their patients. We look forward to working with Abaxis for many years to come."

Dr. Vladimir Ostoich, Abaxis' vice president of marketing for the Pacific Rim, said, "Our distribution arrangement with CSC will be more direct to the end user healthcare provider than the traditional four-tier distribution process utilized in Japan by western companies. We believe this will represent a significant competitive advantage for Abaxis and will help us to make inroads into this critical market."

About Abaxis, Inc.

Abaxis develops, manufactures and markets portable blood analysis systems for use in any patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram, portable analyzer and a series of 8-cm diameter single-use plastic discs, called rotors or reagent discs that contain all the reagents necessary to perform a fixed menu of tests. The system can be operated with minimal training and perform multiple tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory.

This press release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. ABAXIS claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. Specific forward-looking statements contained in this press release include, but are not limited to, risks and uncertainties related to the market acceptance of the Company's products and the continuing development of its products, risks associated with manufacturing and distributing its products on a commercial scale, risks associated with entering the human diagnostic market on a larger scale, risks involved in carrying of inventory, risks from unexpected problems or delays in the Company's manufacturing facility, risks associated with the ability to attract and retain competent sales personnel, general market conditions, competition, risks and uncertainties related to its ability to raise capital in order to fund its operations and other risks detailed from time to time in ABAXIS' periodic reports filed with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statement was made. ABAXIS does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Contact: Clint Severson Lytham Partners, LLC

Chief Executive Officer Joe Dorame, Robert Blum and Joe Diaz

Abaxis, Inc. 602-889-9700

510-675-6500


'/>"/>
SOURCE Abaxis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... , ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 ... image mannequin art competition. Selected from 15 submissions from around the nation, the top ... 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , This year, ...
(Date:2/24/2017)... ... 24, 2017 , ... Castle Farms, the celebrated Northern ... with the winning couple announced on Feb. 14, 2017, on Facebook. The free ... vendors: A Matter of Taste, Ryan Rousseau Enterprises, A Touch of Spring and ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which is ... in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) ... website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients and ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information ... National Institute for Health and Care Excellence (NICE) framework. The agreement ... Health Service (NHS) to search, order and purchase medical and healthcare-related content through ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 /PRNewswire/ ... USD 330.6 million by 2021 from USD 275.9 ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... industries, increasing spending on pharmaceutical R&D, and growth ... factors driving the market growth for particle counters. ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis ... the global Autism Spectrum Disorder market. The research answers the ... drugs marketed for Autism Spectrum Disorder and their clinical attributes? How ...
(Date:2/23/2017)... Calif., Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), ... solutions for the treatment of chronic pain, today reported financial ... 31, 2016. 2016 Accomplishment & Highlights: ... year 2016, an increase of 228% as reported, over the ... 2016, an increase of 612% over the prior year ...
Breaking Medicine Technology: